15353-j-veluchamy

7 Curriculum vitae / List of publications | 171 List of publications 1. A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells. de Bruin RCG, Veluchamy JP, Lougheed SM, Schneiders FL, Lopez-Lastra S, Lameris R, Stam AG, Sebestyen Z, Kuball J, Molthoff CFM, Hooijberg E, Roovers RC, Santo JPD, van Bergen En Henegouwen PMP, Verheul HMW, de Gruijl TD, van der Vliet HJ. Oncoimmunology. 2017 Oct 20;7(1):e1375641. doi: 10.1080/2162402X.2017.1375641. eCollection 2017. 2. The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments. Veluchamy JP*, Kok N*, van der Vliet HJ, Verheul HMW, de Gruijl TD, Spanholtz J. Front Immunol. 2017 May 31;8:631. doi: 10.3389/fimmu.2017.00631. eCollection 2017. Review. 3. Standardized and flexible eight colour flow cytometry panels harmonized between different laboratories to study human NK cell phenotype and function. Veluchamy JP*, Delso-Vallejo M*, Kok N, Bohme F, Seggewiss-Bernhardt R, van der Vliet HJ, de Gruijl TD, Huppert V, Spanholtz J. Sci Rep. 2017 Mar 10;7:43873. doi: 10.1038/srep43873. 4. In Vivo Efficacy of Umbilical Cord Blood Stem Cell-Derived NK Cells in the Treatment of Metastatic Colorectal Cancer. Veluchamy JP*, Lopez-Lastra S*, Spanholtz J, Bohme F, Kok N, Heideman DA, Verheul HM, Di Santo JP, de Gruijl TD, van der Vliet HJ. Front Immunol. 2017 Feb 6;8:87. doi: 10.3389/fimmu.2017.00087. eCollection 2017. 5. Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells. Grimaldi F, Potter V, Perez-Abellan P, Veluchamy JP, Atif M, Grain R, Sen M, Best S, Lea N, Rice C, Pagliuca A, Mufti GJ, Marsh JCW, Barber LD. Biol Blood Marrow Transplant. 2017 Feb;23(2):293-299. doi: 10.1016/j. bbmt.2016.11.003. Epub 2016 Nov 2. 6. High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status. Veluchamy JP*, Heeren AM*, Spanholtz J, van Eendenburg JD, Heideman DA, Kenter GG, Verheul HM, van der Vliet HJ, Jordanova ES, de Gruijl TD. Cancer Immunol Immunother. 2017 Jan;66(1):51-61. doi: 10.1007/s00262-016-1919-1. Epub 2016 Oct 25.